Highlights

  • FPH’s dividend is strongly covered with a ~65% payout ratio supported by robust earnings and cash flow growth.
  • The company maintains a net cash balance sheet, eliminating interest risk and strengthening dividend safety.
  • Dividend growth is steady, but the yield remains low due to FPH’s premium growth valuation.

Fisher & Paykel Healthcare Dividend Sustainability: Is This the Safest Dividend on the NZX?

Introduction: Why FPH Dividend Looks Small but Exceptionally Safe

Fisher & Paykel Healthcare Corporation Ltd (NZX:FPH) is New Zealand’s largest listed company and one of its strongest global performers, yet it does not appear as a high-yield stock. With a yield of around 1.4%, it sits at the opposite end of the income spectrum compared to typical dividend screens. This is because FPH is fundamentally a global growth company, where investors primarily pay for earnings expansion and long-term capital appreciation rather than immediate income.

Despite the low yield, the dividend story is exceptionally strong. The key question is not whether the dividend is attractive in size, but whether it is safe and capable of continuing to grow. On all major financial measures — earnings, cash flow, and balance sheet strength — the answer is clearly positive.

Company Overview: A Global Medical Technology Growth Leader

Fisher & Paykel Healthcare designs and manufactures medical devices focused on respiratory care, including hospital-based respiratory support systems and homecare sleep-apnoea treatments. The company sells into more than 120 countries, with the majority of revenue generated outside New Zealand.

Its competitive strength comes from high-value intellectual property, leading positions in respiratory humidification technologies, and strong hospital adoption of its systems in intensive care and surgical applications. The business invests heavily in research and development, enabling sustained product innovation and long-term growth. While demand surged during the pandemic, post-pandemic normalization has stabilised, and underlying structural growth drivers remain intact.

Dividend Profile: Fully Imputed and Consistently Growing

FPH pays dividends semi-annually and has a long record of uninterrupted growth. The FY26 total dividend reached 52.0 cents per share, representing growth of approximately 22% year-on-year. The interim dividend of 19.0 cents was followed by a final dividend of 33.0 cents, reflecting strong underlying earnings expansion.

A key advantage for New Zealand investors is that FPH dividends are fully imputed, meaning shareholders receive tax credits for company tax already paid in New Zealand. This enhances the after-tax value of the dividend and strengthens its appeal for domestic income investors. Importantly, there have been no dividend cuts or disruptions in its history, reinforcing its reputation for consistency.

Dividend Sustainability Analysis: Strong Earnings, Strong Cash Flow, Zero Net Debt Risk

FPH reported FY26 revenue of approximately NZ$2.31 billion, representing double-digit growth, and net profit of around NZ$468.5 million, up more than 20% year-on-year. Earnings per share reached approximately 79.8 cents, placing the 52.0-cent dividend at a payout ratio of about 65%, which is conservative for a growth company.

Operating cash flow also strengthened significantly, reaching around NZ$663 million. This level of cash generation comfortably funds dividends while still allowing heavy reinvestment into manufacturing capacity and R&D. The most important structural advantage supporting dividend safety is FPH’s net cash position of approximately NZ$237 million, meaning it has no reliance on external debt financing and no interest burden reducing distributable cash flow.

This combination of strong earnings growth, high cash conversion, and a net cash balance sheet places FPH in one of the strongest dividend safety positions on the NZX. Even during periods of currency volatility or tariff pressure, the company retains substantial flexibility to continue increasing dividends.

Sector Context: High-Margin Medical Device Growth Engine

FPH operates in the global medical devices sector, specifically respiratory and sleep-care technology. Demand is supported by long-term structural drivers such as ageing populations, increasing prevalence of sleep disorders, and growing hospital demand for non-invasive respiratory support technologies.

However, the business is exposed to foreign exchange movements due to offshore sales and manufacturing footprint in New Zealand and Mexico. US tariffs also present a manageable but persistent cost headwind. Despite these pressures, FPH has continued to expand margins, showing strong pricing power and operational resilience.

Red Flags: Limited Risks, But Valuation Matters

The key limitation for investors is not dividend safety but income yield. At around 1.4%, the dividend provides minimal current income, making FPH unsuitable for income-focused portfolios. The second consideration is valuation risk, as the market prices the stock at a premium due to its strong growth outlook.

External risks include currency volatility and US tariff exposure, which could impact margins if they intensify. However, these risks primarily affect earnings growth rather than dividend stability, which remains strongly protected by cash flow and balance sheet strength.

Bull Case: A Rare Combination of Growth and Dividend Safety

The bull case rests on FPH’s ability to continue delivering double-digit earnings growth while steadily increasing its dividend. FY26 results demonstrated strong revenue growth of around 14% and profit growth exceeding 20%, supported by expanding margins and strong demand in both hospital and homecare divisions.

With no debt, strong cash generation, and a consistent track record of dividend growth, FPH represents a rare combination of growth stock dynamics with high dividend security. For long-term investors, the dividend acts as a steadily rising income stream layered on top of capital appreciation.

Bear Case: Income Is Limited, Not Risky

The downside argument for FPH is not dividend failure but income inadequacy. The yield remains low because the market values the company as a growth asset rather than an income provider. If earnings growth slows or valuation compresses, total returns could moderate.

Tariffs, currency fluctuations, and global healthcare reimbursement changes could affect margins, but none of these factors meaningfully threaten dividend sustainability given the company’s net cash position and strong cash flow generation.

Latest News and Recent Developments

FY26 results confirmed strong performance with revenue of approximately NZ$2.31 billion and net profit of about NZ$468.5 million, reflecting robust double-digit growth. Operating cash flow increased significantly to around NZ$663 million, supporting both reinvestment and dividend expansion.

The FY26 dividend increased to 52.0 cents per share, up around 22%, fully imputed, and supported by continued earnings momentum. Margins expanded despite US tariff pressures, reflecting strong operational execution and pricing power. The company continues to maintain a net cash position, reinforcing balance sheet strength.

Dividend Sustainability Rating: Sustainable

FPH earns a high-conviction sustainable rating. The dividend is supported by a ~65% payout ratio, strong earnings growth, robust operating cash flow, and a net cash balance sheet of approximately NZ$237 million. The combination of growth, cash generation, and financial strength makes the dividend one of the most secure on the NZX. The only limitation is the structurally low yield, which reflects valuation rather than dividend weakness.

Investor Takeaway

Fisher & Paykel Healthcare is not a high-yield stock but a high-quality dividend growth compounder. Its payout is fully covered, consistently growing, and supported by one of the strongest balance sheets in the NZX universe. For investors seeking income today, the yield is too small to be meaningful. For those focused on long-term dividend growth and capital stability, FPH represents one of the most reliable dividend profiles available.

FAQs

This article is general news commentary only and is not financial advice.